JANUARY 6, 2011; Direct Strategy completes an investment in Theragenics. Theragenics Corporation® is a medical device company serving the surgical products and prostate cancer treatment markets. Its brachytherapy business manufactures and markets its premier product, the palladium-103 TheraSeed® device and I-Seed, an iodine-125 based device. These devices are primarily used in the minimally invasive treatment of localized prostate cancer. "Our investment in Theragenics simply amplifies our commitment to strong intellectual properties and a proven management team", said Antonio De La Rosa, Managing Director of Direct Strategy.